
|Videos|November 13, 2013
The Potential of CAR-Modified T Cells in Hematologic Cancers
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, discusses the potential of using CAR-modified T cells to treat hematologic cancers.
Advertisement
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the potential of using CAR-modified T cells to treat hematologic cancers.
Clinical Pearls
- If utilized in the proper context, CAR-modified T cells have a role in the treatment of CLL
- CAR-modified T cells have the potential to become the standard of care for the treatment of relapsed B-cell acute lymphoblastic leukemia (ALL)
- Researchers are still learning how to optimize the best way of infusing the cells to get the best response rates
- Pharmaceutical companies are starting to gain interest in cellular therapies because of its potential to treat B-cell cancers as well as other types of cancer
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5


















